Acute Coronary Syndrome
Conditions
Brief summary
To evaluate the impact of clinical pharmacist-led discharge education service in patients with acute coronary syndrome.
Detailed description
This prospective, randomized controlled study was conducted in patients with acute coronary syndrome in an cardiology service of tertiary training and research hospital. The clinical pharmacist, within the scope of the discharge education services, provided medication reconciliation, medication review, individually prepared patient medicine (pill) card, patient education (based on Health Belief Model by using written material and video, and verbally \[by using Teach back method especially for patients with low health literacy\]) and counseling (using behavior change techniques based on The Capability, Opportunity, and Motivation Behavior model). The control group received standard care.
Interventions
BEHAVIORALDischarge Education Program
medication reconciliation, medication review, individually prepared patient medicine (pill) card, patient education (based on Health Belief Model by using written material and video, and verbally \[by using Teach back method especially for patients with low health literacy\]) and counseling (using behavior change techniques based on The Capability, Opportunity, and Motivation Behavior model).
Sponsors
Marmara University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients admitted to the cardiology department due to acute coronary syndrome * Older than 18 years old
Exclusion criteria
* Patients who transferred to another ward * Patients with active malignancy * Patients with alzheimer and/or dementia diagnosis * Patient with \>%80 visual loss or deaf muteness reported at medical record
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 30 days hospital re-admission for cardiac reasons | 30 days | Proportion of patients readmitted to hospital for cardiac cause at 1 month |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospital re-admission for any reasons | 1 month, 3 months, 6 months, and 12 months | Proportion of patients readmitted to hospital for any cause through 1 year. |
| Emergency service visits | 1 month, 3 months, 6 months, and 12 months | Proportion of patients visited to emergency service through 1 year. |
| Major Adverse Cardiovascular Event | 1 month, 3 months, 6 months, and 12 months | Proportion of patients had major adverse cardiovascular event through 1 year. |
| Death for cardiac reason | 1 month, 3 months, 6 months, and 12 months | Proportion of patients died for cardiac cause through 1 year. |
| Hospital re-admission for cardiac reasons | 3 months, 6 months, and 12 months | Proportion of patients readmitted to hospital for cardiac cause through 1 year. |
| Medication Adherence | 1 month, 3 months, 6 months, and 12 months | Adherence to Cardioprotective Medications (Clopidogrel, Statins, Beta-blockers, Angiotensin-converting enzyme (ACE) inhibitors/ Angiotensin receptor blocker (ARB) through 1 year assessed by Medication Adherence Report Scale (MARS). MARS assesses adherence through 5-item, summed to give a scale score ranging from 5 to 25, where higher scores indicate higher levels of reported adherence. |
| Quality of Life Measurement | 1 month, 3 months, 6 months, and 12 months | Change in quality of life from baseline assessed with EuroQol questionnaire EQ-5D-3L through 1 year. (EQ-5D-3L) is a standardized scale for use as a measure of the quality of life. The EQ-5D-3L descriptive system comprises the following 5 dimensions (5D): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels (3L): no problems (1 point), some problems (2 points), extreme problems (3 points). This gives a total of 245 different health states, adding unconscious and dead. |
| Achieved Target Low-density Lipoprotein Value | 6 months, 12 months | Rate of patients achieved target low-density lipoprotein value |
| Death for any reason | 1 month, 3 months, 6 months, and 12 months | Proportion of patients dying for any cause through 1 year. |
Countries
Turkey (Türkiye)
Outcome results
None listed